Tilray Brands Inc is a global leader in the cannabis industry, specializing in the cultivation, production, and distribution of a diverse range of cannabis products
The company operates across various segments, including medical and recreational cannabis, as well as hemp-derived wellness products. Tilray focuses on innovation and quality, offering a portfolio that encompasses various formats such as dried flower, oils, edibles, and beverages. In addition to its core cannabis business, Tilray is dedicated to advancing research, education, and consumer awareness within the rapidly evolving market, positioning itself as a key player in the development and expansion of cannabis-related offerings worldwide.
A drug reform advocate has revealed that the Trump administration is inviting proposals for federal marijuana legalization. The activist said that they attended a recent event where they discussed the matter of federal cannabis reform with a White House staffer and were invited to write a proposal explaining why President Trump should support legalizing cannabis at the federal level.
A drug reform advocate has revealed that the Trump administration is inviting proposals for federal marijuana legalization. The activist said that they attended a recent event where they discussed the matter of federal cannabis reform with a White House staffer and were invited to write a proposal explaining why President Trump should support legalizing cannabis at the federal level.
NEUMÜNSTER, Germany, March 11, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, is pleased to announce the introduction of Tilray Craft, a new brand extension of the Tilray Medical brand within its medical cannabis portfolio in Germany.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Shareholders of Tilray would probably like to forget the past six months even happened. The stock dropped 54.1% and now trades at $0.87. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Involving cannabis industry players in marijuana testing could help U.S. states address testing lab fraud, scientist David Vaillencourt says. Testing is critical to ensuring the cannabis products entering the U.S. market are free from potentially harmful contaminants like heavy metals, residual solvents, and bacteria. However, data has consistently shown that America’s state-approved cannabis industry is awash with untested products.
Involving cannabis industry players in marijuana testing could help U.S. states address testing lab fraud, scientist David Vaillencourt says. Testing is critical to ensuring the cannabis products entering the U.S. market are free from potentially harmful contaminants like heavy metals, residual solvents, and bacteria. However, data has consistently shown that America’s state-approved cannabis industry is awash with untested products.
More than a decade after states began legalizing recreational cannabis, the U.S. marijuana industry remains complex. On one side, marijuana has become as common for some as a cold beer or a glass of wine, with regulated companies offering products that meet government standards. Yet, a significant portion of cannabis sales in the country still comes from illegal operations.
